000157048 001__ 157048
000157048 005__ 20240229123127.0
000157048 0247_ $$2doi$$a10.1016/j.ygyno.2020.06.481
000157048 0247_ $$2pmid$$apmid:32641237
000157048 0247_ $$2ISSN$$a0090-8258
000157048 0247_ $$2ISSN$$a1095-6859
000157048 0247_ $$2altmetric$$aaltmetric:85781388
000157048 037__ $$aDKFZ-2020-01339
000157048 041__ $$aeng
000157048 082__ $$a610
000157048 1001_ $$aBrieger, Katharine K$$b0
000157048 245__ $$aMenopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival.
000157048 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2020
000157048 3367_ $$2DRIVER$$aarticle
000157048 3367_ $$2DataCite$$aOutput Types/Journal article
000157048 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1602676186_15239
000157048 3367_ $$2BibTeX$$aARTICLE
000157048 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000157048 3367_ $$00$$2EndNote$$aJournal Article
000157048 500__ $$a2020 Sep;158(3):702-709
000157048 520__ $$aPrior studies of menopausal hormone therapy (MHT) and ovarian cancer survival have been limited by lack of hormone regimen detail and insufficient sample sizes. To address these limitations, a comprehensive analysis of 6419 post-menopausal women with pathologically confirmed ovarian carcinoma was conducted to examine the association between MHT use prior to diagnosis and survival.Data from 15 studies in the Ovarian Cancer Association Consortium were included. MHT use was examined by type (estrogen-only (ET) or estrogen+progestin (EPT)), duration, and recency of use relative to diagnosis. Cox proportional hazards models were used to estimate the association between hormone therapy use and survival. Logistic regression and mediation analysis was used to explore the relationship between MHT use and residual disease following debulking surgery.Use of ET or EPT for at least five years prior to diagnosis was associated with better ovarian cancer survival (hazard ratio, 0.80; 95% CI, 0.74 to 0.87). Among women with advanced stage, high-grade serous carcinoma, those who used MHT were less likely to have any macroscopic residual disease at the time of primary debulking surgery (p for trend <0.01 for duration of MHT use). Residual disease mediated some (17%) of the relationship between MHT and survival.Pre-diagnosis MHT use for 5+ years was a favorable prognostic factor for women with ovarian cancer. This large study is consistent with prior smaller studies, and further work is needed to understand the underlying mechanism.
000157048 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000157048 588__ $$aDataset connected to CrossRef, PubMed,
000157048 7001_ $$aPeterson, Siri$$b1
000157048 7001_ $$aLee, Alice W$$b2
000157048 7001_ $$aMukherjee, Bhramar$$b3
000157048 7001_ $$aBakulski, Kelly M$$b4
000157048 7001_ $$aAlimujiang, Aliya$$b5
000157048 7001_ $$aAnton-Culver, Hoda$$b6
000157048 7001_ $$aAnglesio, Michael S$$b7
000157048 7001_ $$aBandera, Elisa V$$b8
000157048 7001_ $$aBerchuck, Andrew$$b9
000157048 7001_ $$aBowtell, David D L$$b10
000157048 7001_ $$aChenevix-Trench, Georgia$$b11
000157048 7001_ $$aCho, Kathleen R$$b12
000157048 7001_ $$aCramer, Daniel W$$b13
000157048 7001_ $$aDeFazio, Anna$$b14
000157048 7001_ $$aDoherty, Jennifer A$$b15
000157048 7001_ $$0P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aFortner, Renée T$$b16$$udkfz
000157048 7001_ $$aGarsed, Dale W$$b17
000157048 7001_ $$aGayther, Simon A$$b18
000157048 7001_ $$aGentry-Maharaj, Aleksandra$$b19
000157048 7001_ $$aGoode, Ellen L$$b20
000157048 7001_ $$aGoodman, Marc T$$b21
000157048 7001_ $$aHarris, Holly R$$b22
000157048 7001_ $$aHøgdall, Estrid$$b23
000157048 7001_ $$aHuntsman, David G$$b24
000157048 7001_ $$aShen, Hui$$b25
000157048 7001_ $$aJensen, Allan$$b26
000157048 7001_ $$aJohnatty, Sharon E$$b27
000157048 7001_ $$aJordan, Susan J$$b28
000157048 7001_ $$aKjaer, Susanne K$$b29
000157048 7001_ $$aKupryjanczyk, Jolanta$$b30
000157048 7001_ $$aLambrechts, Diether$$b31
000157048 7001_ $$aMcLean, Karen$$b32
000157048 7001_ $$aMenon, Usha$$b33
000157048 7001_ $$aModugno, Francesmary$$b34
000157048 7001_ $$aMoysich, Kirsten$$b35
000157048 7001_ $$aNess, Roberta$$b36
000157048 7001_ $$aRamus, Susan J$$b37
000157048 7001_ $$aRichardson, Jean$$b38
000157048 7001_ $$aRisch, Harvey$$b39
000157048 7001_ $$aRossing, Mary Anne$$b40
000157048 7001_ $$aTrabert, Britton$$b41
000157048 7001_ $$aWentzensen, Nicolas$$b42
000157048 7001_ $$aZiogas, Argyrios$$b43
000157048 7001_ $$aTerry, Kathryn L$$b44
000157048 7001_ $$aWu, Anna H$$b45
000157048 7001_ $$aHanley, Gillian E$$b46
000157048 7001_ $$aPharoah, Paul$$b47
000157048 7001_ $$aWebb, Penelope M$$b48
000157048 7001_ $$aPike, Malcolm C$$b49
000157048 7001_ $$aPearce, Celeste Leigh$$b50
000157048 7001_ $$aConsortium, Ovarian Cancer Association$$b51$$eCollaboration Author
000157048 773__ $$0PERI:(DE-600)1467974-7$$a10.1016/j.ygyno.2020.06.481$$gp. S0090825820322964$$n3$$p702-709$$tGynecologic oncology$$v153$$x0090-8258$$y2020
000157048 909CO $$ooai:inrepo02.dkfz.de:157048$$pVDB
000157048 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000157048 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000157048 9141_ $$y2020
000157048 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2020-01-03$$wger
000157048 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bGYNECOL ONCOL : 2018$$d2020-01-03
000157048 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-01-03
000157048 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-01-03
000157048 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2020-01-03
000157048 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-01-03
000157048 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-01-03
000157048 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-01-03
000157048 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-01-03
000157048 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index$$d2020-01-03
000157048 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-01-03
000157048 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-01-03
000157048 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-01-03
000157048 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-01-03
000157048 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-01-03
000157048 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2020-01-03
000157048 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000157048 980__ $$ajournal
000157048 980__ $$aVDB
000157048 980__ $$aI:(DE-He78)C020-20160331
000157048 980__ $$aUNRESTRICTED